The Ohio State University

“NGS generates a significant amount of data and the process of developing clinically useful reports from this data is time consuming. The GO Clinical Workbench has helped us reduce the time to develop a clinically actionable report from half a day to less than an hour.”
— Pamela Groen, Laboratory Manager, the Ohio State University, College of Medicine, Dept Of Pathology

Read the Press Release

med fusion

“Our laboratory employs a multi-technology approach to solid tumor profiling in order to present a more complete set of treatment options as defined by the laboratory results. Our partnership with GenomOncology combines these laboratory results with the peer-reviewed clinical expertise and clinical trial matching methodology of My Cancer Genome.”
— Jon Hart, CEO, med fusion

Read the Press Release

Hawai’i Pathologists’ Laboratory

“With the GO Clinical Workbench we can accumulate critical knowledge about genetic variants that are clinically relevant or benign across diverse ancestry, such as as Japanese, European, and Polynesian. Combining that local expertise with the well curated data already built into GenomOncology’s systems, our lab can continuously learn about these populations, and ultimately, offer better care.”
— Chris Lum, MD, Pathologist, Hawai’i Pathologists’ Laboratory

Read the Press Release


Children’s National Medical Center

“The Children’s National’s Pediatric Genomic Initiative is one of the first in the world to launch clinical testing based on a medical exome (4,813 genes) to carve out personalized sequencing panels (PSPs) that can be customized by clinical presentation, and we are extremely pleased with the results. GenomOncology has tailored the GO Clinical Workbench specifically to our needs and laboratory workflow including the ability to generate our PSP offerings by gene list, clinical indication, and by leveraging our chromosomal microarray data to guide testing.”
— Sean Hofherr, PhD, Director of the Molecular Diagnostic Lab at Children’s National Medical Center

Read the Press Release


Thomas Jefferson University Hospital

“For many diseases we deal with at Jefferson, the best results are obtained by applying multiple analytical techniques. This is especially true for AML, for which karyotype analysis, fluorescence in situ hybridization, and next generation DNA sequencing provide complementary information. Bringing the results of each of those together in the GO Clinical Workbench for interpretation and reporting simplifies our efforts and provides greater clarity to the oncologists our laboratory serves.”
— Stephen C. Peiper, MD, Chair of the Department of Pathology, Anatomy and Cell Biology, Thomas Jefferson University Hospital

Read the Press Release        |        Read the Case Study